Literature DB >> 10465342

CD24 is a marker for human breast carcinoma.

M Fogel1, J Friederichs, Y Zeller, M Husar, A Smirnov, L Roitman, P Altevogt, Z M Sthoeger.   

Abstract

CD24 is a small, mucin-type glycosylphosphatidylinositol-linked cell surface molecule expressed by neutrophils, pre B lymphocytes and certain human tumor cell lines. CD24 has been identified as a ligand for P-selectin in both mouse and human cells. We previously reported that the P-selectin-CD24 binding pathway is important for the binding of the breast carcinoma cell line KS to platelets and the rolling of these cells on endothelial P-selectin. In the present study we have analyzed the expression of CD24 on human breast carcinoma cell lines and on fresh breast carcinoma specimens using the CD24-specific antibody ML-5. Our study clearly demonstrates that CD24 is abundantly expressed on cell lines and fresh tissues of breast carcinomas. We find a differential expression of CD24 in breast carcinomas (cytoplasmic pattern) versus benign breast lesions (apical pattern). Moreover, the intensity of CD24 expression increases with the histological grade of the tumor. Thus, CD24 expression might be a useful marker for human breast carcinoma and play a role in facilitating metastasis by the interaction between tumor cells and platelets or endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465342     DOI: 10.1016/s0304-3835(99)00195-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

1.  CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.

Authors:  Sibel Bektas; Burak Bahadir; Bulent Hamdi Ucan; Sukru Oguz Ozdamar
Journal:  Pathol Oncol Res       Date:  2010-02-23       Impact factor: 3.201

2.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

Authors:  J B Welsh; P P Zarrinkar; L M Sapinoso; S G Kern; C A Behling; B J Monk; D J Lockhart; R A Burger; G M Hampton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin.

Authors:  Ja Hye Myung; Khyati A Gajjar; Ryan M Pearson; Cari A Launiere; David T Eddington; Seungpyo Hong
Journal:  Anal Chem       Date:  2011-01-05       Impact factor: 6.986

4.  Prognostic significance of CD24 expression in gastric carcinoma.

Authors:  Nevine S Darwish; Min A Kim; Mee Soo Chang; Hye Seung Lee; Byung Lan Lee; Yong Il Kim; Woo Ho Kim
Journal:  Cancer Res Treat       Date:  2004-10-30       Impact factor: 4.679

5.  Preparation of epithelial and mesenchymal stem cells from murine mammary gland.

Authors:  Ian Guest; Zoran Ilic; Jun Ma
Journal:  Curr Protoc Toxicol       Date:  2011-11

6.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.

Authors:  Alvin Y Liu; Martine P Roudier; Lawrence D True
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

7.  Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer.

Authors:  Min Hye Jang; Hyun Jong Kang; Ki Seok Jang; Seung Sam Paik; Wan Seop Kim
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

Review 8.  Tumour biological aspects of CD24, a mucin-like adhesion molecule.

Authors:  G Kristiansen; M Sammar; P Altevogt
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

9.  CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.

Authors:  Glen Kristiansen; Carsten Denkert; Karsten Schlüns; Edgar Dahl; Christian Pilarsky; Steffen Hauptmann
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

10.  Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.

Authors:  Germana Rappa; Aurelio Lorico
Journal:  Exp Cell Res       Date:  2010-01-11       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.